Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) SEC filings page on Stock Titan provides access to the company’s public filings and related disclosures as they appear in the U.S. Securities and Exchange Commission’s EDGAR system. Mirum is a biopharmaceutical and rare disease company with approved therapies such as LIVMARLI, CHOLBAM and CTEXLI and a pipeline that includes volixibat, brelovitug and MRM-3379, as described in its press releases.
Through this page, users can review Mirum’s current and historical filings, including Form 8-K reports that describe material events. Recent 8-K filings have covered topics such as an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, associated private placement subscription agreements, and corporate updates on financial results. Other 8-K disclosures include receipt of a Paragraph IV Certification Notice Letter related to a generic version of LIVMARLI and press releases furnished as exhibits discussing quarterly results.
Stock Titan enhances these documents with AI-powered summaries designed to highlight the main points of lengthy filings. For example, AI summaries can help readers quickly understand key terms of merger agreements, private placement structures, or the implications of patent-related notices referenced in Mirum’s 8-Ks. Users can also monitor unregistered sales of equity securities and other capital markets activities described in the filings.
This page updates as new Mirum filings are posted to EDGAR, giving investors and researchers a structured way to follow regulatory disclosures alongside the company’s rare disease commercial and development programs. Forms such as 10-K, 10-Q and additional 8-Ks, when available, can be reviewed with AI-generated insights to assist in interpreting Mirum’s reporting.
An affiliate of MIRM has filed a Rule 144 notice to sell 2,000 shares of common stock on NASDAQ through Morgan Stanley Smith Barney. These shares were acquired from the issuer via a stock option exercise for cash on 01/15/2026, the same date targeted for the sale. As context, the filing lists 51,393,574 shares of the issuer’s common stock outstanding.
Over the prior three months, the person named in the filing, Saira Ramasastry, sold 5,000 common shares on 12/22/2025 for gross proceeds of $400,000.00 and 2,000 common shares on 12/18/2025 for gross proceeds of $139,460.00.
Mirum Pharmaceuticals furnished a current report describing new investor information. The company issued a press release with preliminary unaudited net product sales for the year ended December 31, 2025, including sales for its liver disease medicines LIVMARLI (maralixibat), CHOLBAM and CTEXLI, along with preliminary unaudited cash, cash equivalents and investments.
Mirum also posted an updated corporate slide presentation on its website in connection with the J.P. Morgan Healthcare Conference, and furnished this presentation as an exhibit. Both the press release and the investor presentation are being furnished rather than filed, which means they are not automatically incorporated into other SEC reports unless specifically referenced.
Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics through a two-step merger, adding worldwide rights to brelovitug, a late-stage antibody for chronic hepatitis D and B. At closing Mirum will pay Target security holders an upfront $250 million in cash plus up to 5,196,009 Mirum shares, valued at about $370 million based on a recent volume-weighted average price, with up to $200 million in additional cash milestones tied to future net sales. The deal is subject to antitrust clearance, Bluejay shareholder approval and other customary conditions, with closing expected in the first quarter of 2026.
To help fund the transaction, Mirum arranged a $200 million private placement, selling 2,385,149 common shares and pre-funded warrants for 536,412 shares at $68.48 per share (or $68.4799 per warrant). The brelovitug program has FDA breakthrough therapy designation and EMA PRIME status for HDV and is in a global Phase 3 AZURE program, with key interim and top-line data readouts anticipated from 2026 through 2028. Mirum also highlighted upcoming clinical catalysts across volixibat, Livmarli and MRM-3379, including planned regulatory filings and potential launches if approvals are obtained.
Mirum Pharmaceuticals (MIRM) director reports option exercise and share sale. On 11/21/2025, the reporting person exercised a stock option for 50,000 shares of common stock at $2.936 per share and acquired the shares. On the same day, they sold 50,000 shares of common stock at $70 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, the director reported no directly held common shares, but continued to report indirect ownership of 186,410 shares through The Grey Family Trust dated November 12, 1999 and 93,750 shares through The Grey 2018 Irrevocable Children's Trust. They also reported 281,176 stock options beneficially owned following the transactions, with the option referenced in this filing fully vested and exercisable.
Mirum Pharmaceuticals, Inc. (MIRM) reported an insider equity transaction by its Chief Executive Officer, who is also a director. On 11/18/2025, the reporting person exercised an employee stock option to buy 19,133 shares of common stock at an exercise price of $19.24 per share, coded as transaction type "M" for an option exercise.
Following this transaction, the reporting person beneficially owns 158,034 shares of Mirum common stock directly and 208,570 shares indirectly through The Peetz Family Trust. The filing notes that the stock option involved in this transaction is fully vested and that the direct holdings include 260 shares acquired on November 10, 2025 under the company’s Employee Stock Purchase Plan.
Mirum Pharmaceuticals, Inc. reported that it received a Paragraph IV Certification Notice Letter from Sandoz, Inc., which has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market a generic version of Mirum’s drug Livmarli (maralixibat). Sandoz alleges that five Livmarli patents listed in the FDA Orange Book are invalid, unenforceable, or not infringed by its proposed generic. Under U.S. law, Mirum may file a patent infringement lawsuit within 45 days of receiving the notice, which would trigger an automatic 30-month stay on final FDA approval of the ANDA. Mirum states that it plans to vigorously enforce its intellectual property, promptly sue Sandoz and any other ANDA filers, and seek a permanent injunction against generic versions that would infringe its patents.
Mirum Pharmaceuticals (MIRM) reported strong Q3 2025 results. Product sales, net reached $133,010 thousand, up from $90,302 thousand a year ago, driven by Livmarli at $92,235 thousand and Bile Acid Medicines at $40,775 thousand. The company posted net income of $2,905 thousand, or $0.05 diluted EPS, versus a loss last year.
Cash and cash equivalents were $282,021 thousand, with unrestricted cash, cash equivalents and investments of $378.0 million as of September 30, 2025. Year‑to‑date operating cash flow was $49,760 thousand. Stockholders’ equity rose to $292,046 thousand from $225,640 thousand at year‑end. Principal on the 4.00% Convertible Senior Notes due 2029 was $316,233 thousand; the notes met conversion conditions in Q3 and Q4 2025, and conversions to date were not material. Total U.S. product sales were $103,713 thousand, with $29,297 thousand from the rest of the world. Common shares outstanding were 51,393,574 as of October 31, 2025.
Mirum Pharmaceuticals, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into this report. The company also specifies that this information is being furnished, not filed, which limits how it is treated under securities laws and how it may be incorporated into other regulatory documents.
Mirum Pharmaceuticals reported a Form 144 notice showing a proposed sale of 17,000 common shares to be executed through Morgan Stanley Smith Barney on 09/11/2025. The filing lists an aggregate market value of $1,264,917.30 for the shares against 50,237,647 shares outstanding. The shares were acquired and are being sold on 09/11/2025 as the result of a stock option exercise with payment in cash. The filer certifies they are not aware of undisclosed material adverse information about the issuer. The notice reports no other sales in the past three months.
Insider transactions by a company director: Mirum Pharmaceuticals director Saira Ramasastry exercised a stock option and sold the resulting shares on 09/08/2025. The reporting shows an exercise (code M) of 17,000 shares at a conversion/exercise price of $23.51, followed the same day by a sale (code S) of 17,000 common shares at a weighted average sale price of $77.042178 (range: $76.835–$77.29). The derivative disclosure notes the option is fully vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.